Skip to main content
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. — Investor Relations & Filings

Ticker · CCCC ISIN · US12529R1077 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2021-05-19 Capital/Financing Update
Country US United States of America
Listing US CCCC

About C4 Therapeutics, Inc.

https://c4therapeutics.com/

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of a new class of small-molecule medicines through targeted protein degradation (TPD). The company's proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform is utilized to create therapeutics that selectively destroy disease-causing proteins. C4 Therapeutics' primary focus is on developing treatments for cancer and other diseases. Its clinical pipeline includes investigational candidates such as cemsidomide (CFT7455) for hematologic malignancies, CFT8919 for solid tumors with specific genetic mutations, and CFT1946 for BRAF V600 mutant cancers.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by C4 Therapeutics, Inc. It is a preliminary prospectus related to an initial public offering (IPO) or other securities offering. The text includes detailed information about the offering, company overview, risk factors, underwriting, and other typical sections of a registration statement. It is not an annual report, earnings release, or any other financial report type. It is a capital markets filing related to fundraising and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement of filing, so it is not RPA or RNS. Confidence is high due to clear identification of Form S-1 and registration statement context.
2021-05-19 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2021, reporting the issuance of a press release announcing financial results and business highlights for the quarter ended March 31, 2021. The text explicitly states that the press release is furnished as an exhibit and that the information is not "filed" for purposes of Section 18 of the Exchange Act, indicating this is a current report announcing earnings results rather than the earnings release itself. The document length is 3808 characters, which is relatively short and consistent with an 8-K filing announcing an earnings release. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a current report announcing the earnings release, not the earnings release itself or a full interim report.
2021-05-13 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2021, reporting the departure of a senior officer, specifically the Vice President, Finance, Corporate Controller and Principal Accounting Officer. The content focuses on management changes rather than financial results, audit information, or other report types. The key section is Item 5.02, which relates to departure and appointment of officers. The document length is 3249 characters, which is relatively short and consistent with a management change announcement rather than a full report. Therefore, the document fits the category of Board/Management Information (MANG).
2021-04-30 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as "Definitive Additional Materials" related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document does not contain financial statements or detailed financial data, but rather is related to shareholder voting information. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is short and it is not an announcement of a report but the proxy materials themselves.
2021-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-26 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.